Ocugen Inc

NASDAQ:OCGN  
4.25
+0.23 (+5.72%)
4:29:34 PM EDT: $4.16 -0.09 (-2.12%)
Products

Ocugen Inc Announces FDA Acceptance Of IND Application To Initiate Phase 1/2 Clinical Trial For Gene Therapy Candidate OCU400 To Treat Inherited Retinal Degeneration

Published: 12/09/2021 12:46 GMT
Ocugen Inc (OCGN) - Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate Ocu400 to Treat Inherited Retinal Degeneration.
Ocugen Inc - Trial to Start in Q1 2022 Will Enroll Patients With Mutations in Nr2e3 Or Rho Genes.